Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study

The Lancet Oncology

Volumn 16, Issue 5, 2015, Pages 499-508

  Tabernero, Josep ^a   Yoshino, Takayuki ^b   Cohn, Allen Lee ^c   Obermannova, Radka ^d   Bodoky, Gyorgy ^e   Garcia Carbonero, Rocio ^f   Ciuleanu, Tudor Eliade ^g   Portnoy, David C ^h   Van Cutsem, Eric ⁱ   Grothey, Axel ^j   Prausová, Jana ^k   Garcia Alfonso, Pilar ^l   Yamazaki, Kentaro ^m   Clingan, Philip R ⁿ   Lonardi, Sara ^o   Kim, Tae Won ^p   Simms, Lorinda ^q   Chang, Shao Chun ^q   Nasroulah, Federico ^q  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c Rocky Mountain Cancer Center and US Oncology Research   (United States)

^d MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^e Szent Laszlo Hospital   (Hungary)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^h West Clinic   (United States)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j MAYO CLINIC   (United States)

^k UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^l HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^m SHIZUOKA CANCER CENTER   (Japan)

ⁿ Southern Medical Day Care Centre   (Australia)

^o VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^p University of Ulsan College of Medicine   (South Korea)

^q ELI LILLY AND COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER GROWTH; COLORECTAL CARCINOMA; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; INFUSION RELATED REACTION; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC COLORECTAL CARCINOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VERY ELDERLY; VOMITING; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS;

EID: 84933673498     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70127-0     Document Type: Article

References (26)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 (accessed Nov 4, 2014). http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
2. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 25(suppl 3):iii19.
3. SEER stat fact sheets: colon and rectum cancer Surveillance, EpidemiologyEpidemiology, End Results ProgramEnd Results Program, (accessed March 21, 2015). http://seer.cancer.gov/statfacts/html/colorect.html.
4. Clinical practice guidelines in oncology (NCCN guidelines®) National Comprehensive Care Network, (accessed Nov 20, 2014). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
5. Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
6. Ferrara N Vascular endothelial growth factor. Trends Cardiovasc Med 1993, 3:244-250.
7. Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997, 79:233-269.
8. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008, 26:3523-3529.
9. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
10. Giantonio BJ, Catalano PJ, Meropol JN, et al. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
11. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013, 14:29-37.
12. Van Cutsem E, Tabernero J, Lakomý R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012, 30:3499-3506.
13. Sullivan LA, Brekken RA The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2010, 2:165-175.
14. Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011, 32:88-111.
15. Amini A, Masoumi Moghaddam S, Morris DL, Pourgholami MH The critical role of vascular endothelial growth factor in tumor angiogenesis. Curr Cancer Drug Targets 2012, 12:23-43.
16. Bruns CJ, Liu W, Davis DW, et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000, 89:488-499.
17. Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006, 12:2197-2207.
18. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicenter, placebo-controlled, phase 3 trial. Lancet 2014, 383:31-39.
19. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014, 15:1224-1235.
20. Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014, 384:665-673.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
22. Common terminology criteria for adverse events (CTCAE) version 4.02 US Department of Health and Human Services, (accessed March 21, 2015). http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference:8.5x11.pdf.
23. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
24. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. EuroQoL Group.
25. Tabernero J, Van Cutsem E, Lakomý R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014, 50:320-331.
26. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010, 102:596-604.